Expert Q&A – media

【EXPERT Q&A】‌‌With a large number of main products, which items should an enterprise prioritize for overseas promotion?‌

Drugdu.com expert’s response: When many pharmaceutical and medical device enterprises start overseas promotion, they will encounter a common problem: there are dozens or even hundreds of products in the company’s product catalog, but which ones should be prioritized for key promotion on B2B platforms? Some enterprises are used to uploading all their existing products, believing that the more products they list, the higher the chance of being searched by overseas buyers. Others directly select several best-selling products in the domestic market, assuming that items performing well at home will surely meet demands in overseas markets. Both ideas are reasonable to a certain extent, but more factors need to be taken into account in actual overseas procurement scenarios. Whether a product can attract buyers’ attention is related not only to market demand, but also to the enterprise’s supply capacity, product documentation, target market access status and peer competition. A Large Product ...
- Source: drugdu
- 33
- October 23, 2026
【EXPERT Q&A】‌To what extent should an enterprise prepare when overseas buyers inquire whether products can support local registration?‌

Drugdu.com expert’s response: When conducting foreign trade in pharmaceuticals and medical devices, some overseas buyers, after confirming product specifications and prices, will further ask: “Can you support product registration in our country?” This question may seem straightforward to suppliers. If an enterprise holds relevant certificates such as GMP, CE, or ISO 13485, or has past export experience, it can easily reply directly that it can support registration. However, the “registration support” mentioned by buyers may involve far more work than just providing a few certificates. Especially for pharmaceuticals, APIs and medical devices, there are significant differences in registration pathways, application entities, technical documents and approval requirements across different countries. The fact that a supplier can provide product materials does not mean these materials already meet local registration requirements; nor does the fact that a product has been approved for marketing in one market mean it can directly enter another. What Are ...
- Source: drugdu
- 46
- October 23, 2026
【EXPERT Q&A】What is the process for applying for a medical device registration certificate?

Drugdu.com expert’s response: When applying for a Medical Device Registration Certificate, you should not start by simply asking “what documents to prepare”. The more accurate workflow is to first determine the classification of the medical device, confirm the competent regulatory authority for acceptance, and finally prepare the testing, clinical evaluation, quality system and registration application documents. In China, Class I medical devices are subject to filing management, while Class II and Class III medical devices are subject to registration management. That is to say, the “Medical Device Registration Certificate” in the general sense mainly corresponds to Class II and Class III medical devices. Domestic Class III medical devices, as well as imported Class II and Class III medical devices, are reviewed and approved by the National Medical Products Administration (NMPA); domestic Class II medical devices are generally the responsibility of the provincial drug regulatory authorities. Before initiating the process, the ...
- Source: drugdu
- 68
- October 19, 2026
【EXPERT Q&A】If there are no inquiries for a silver member product one month after its launch, what issues should be checked first?

Drugdu.com expert’s response: Suppliers tend to get extremely anxious when their Silver Member products have been online for a month without receiving any inquiries. This reaction is completely understandable. Enterprises sign up for membership, upload products, and wait for overseas buyers to reach out. After a month with no inquiries, it is easy for them to assume the platform is ineffective or their products have no market demand. However, from the perspective of platform operation, the lack of inquiries in the first month should not be judged solely by the result, nor can it be simply concluded that “there are no buyers”. Especially for B2B products such as pharmaceuticals, medical devices, APIs, excipients and consumables, there is an inherent screening process before buyers officially send an inquiry: from searching, browsing, comparing suppliers to making the final decision. Whether the products can be seen, matched by search algorithms, understood and trusted ...
- Source: drugdu
- 79
- October 16, 2026
【EXPERT Q&A】Why didn’t the buyer contact us again after we got back?

Drugdu.com expert’s response: Many pharmaceutical and medical device enterprises have encountered such a situation when attending exhibitions. They had a great conversation with buyers on site: the buyers listened carefully to the product introduction, asked about specifications, prices, certificates and export experience, and even exchanged business cards or added contact information. At that moment, suppliers would feel that this client is highly promising. However, after the exhibition ends, they have sent the documents and followed up via emails, but the buyers remain unresponsive. This scenario is far from rare, and it cannot be simply interpreted as “the client has no interest” or “the on-site communication was just polite small talk”. In most cases, the on-site conversation at the exhibition is only the first step for buyers to screen suppliers. When attending the exhibition, a buyer may visit dozens of booths in one day, encountering a large number of suppliers offering ...
- Source: drugdu
- 113
- October 14, 2026
【EXPERT Q&A】How to efficiently sort out medical device regulations and corresponding standards?

Drugdu.com expert’s response: When sorting out medical device regulations and standards, the most common mistake is to start reading directly from the regulatory documents themselves. For example, you may immediately dive into MDR, IVDR, FDA Guidance, NMPA announcements, and ISO standard lists. The more materials you read, the more confused you become, and in the end, you cannot figure out exactly what preparation path a specific product should follow. A more efficient approach is to place regulations and standards back into the product scenario first. That is, you need to clarify in advance: which category of product you are sorting out, which market it is intended to enter, what risk class the product belongs to, what documents are required before market launch, and what responsibilities need to be assumed after market launch. Medical device regulations do not exist in isolation, and they must ultimately be applied to a specific product. ...
- Source: drugdu
- 123
- October 12, 2026
【EXPERT Q&A】What certifications are required for the export of food additives to the United States, France, Germany, Japan and South Korea?

Drugdu.com expert’s response: When exporting food additives to the United States, France, Germany, Japan and South Korea, it cannot be simply understood as “getting one single certification to clear customs”. These markets pay more attention to whether the additive is permitted for use in local food, which food categories it can be added to, its maximum usage limit, and whether its quality specifications and label documents meet the local requirements. In other words, exporting food additives is not only about “having a certificate”, but about ensuring that the product itself is legally compliant, its intended use is approved, and the importer can complete the local declaration smoothly. The United States: Focus on FDA compliance and import requirements When exporting to the US, suppliers often claim “we have FDA certification”. But for food additives, obtaining a single FDA certificate does not mean the product can be sold freely. In the US, ...
- Source: drugdu
- 132
- October 9, 2026
【EXPERT Q&A】When an overseas buyer brings up exclusive agency right right at the start of communication, should the supplier immediately proceed with the discussion?

Drugdu.com expert’s response: When doing foreign trade in pharmaceuticals and medical devices, some inquiries may seem very appealing at first glance. The buyer hasn’t asked many detailed product questions, and hasn’t even clarified samples, prices or documents, but they will immediately put forward a request: “Can we be your exclusive distributor?” or “We want to be your exclusive agent in our market.” For suppliers, this type of information can easily arouse expectations. Compared with ordinary price inquiries, exclusive agency sounds more like long-term cooperation, and more like the channel resources that enterprises truly want when expanding overseas. Especially for enterprises that are developing overseas markets, they are already eager to find local agents, distributors or long-term partners. When they see buyers taking the initiative to propose exclusive agency, they will naturally list this lead as a top priority. However, bringing up exclusive agency right at the very beginning does not ...
- Source: drugdu
- 140
- October 7, 2026
【EXPERT Q&A】What are the trends in the medical consumables industry?

Drugdu.com expert’s response: The medical consumables industry is still growing overall, but its growth logic is no longer as simple as “large hospital consumption and fast product turnover”. For those engaged in pharmaceutical and medical device foreign trade and B2B platform operations, what deserves more attention is that while demand remains stable, buyers are raising their requirements for supply stability, compliance documentation, product segmentation and price control. 1. Basic demand remains stable: consumables are “high-frequency rigid necessities” Medical consumables cover a wide range of categories, including gloves, syringes, infusion supplies, catheters, dressings, gauze, surgical packs, non-woven fabric products, disinfection and sterilization supplies, testing consumables, respiratory consumables, incontinence care products, and more. Multiple market reports have identified infection control, chronic disease management, increasing surgical volumes, and the expansion of hospital and home care scenarios as the main growth drivers ^[Grand View Research]^. These products are characterized by high repurchase frequencies, with ...
- Source: drugdu
- 132
- October 5, 2026
【EXPERT Q&A】What are the principle of action and advantages of peptide-conjugated radionuclide drugs (PRC)?

Drugdu.com expert’s response: Peptide-radionuclide conjugates, in common contexts, are often categorized under PRRT (Peptide Receptor Radionuclide Therapy) or radiopharmaceutical conjugates. Its core concept can be summed up in one sentence: the peptide is responsible for “targeting the site”, while the radionuclide takes charge of “killing tumor cells”. This type of drug usually consists of several parts: a peptide that can recognize tumor-associated receptors, a linker/chelation structure, and a radionuclide for diagnosis or therapy. The peptide segment binds to specific receptors highly expressed on the surface of tumor cells, such as the somatostatin receptors commonly seen in neuroendocrine tumors. After binding, the receptor-peptide complex can be internalized by the cell, and the radionuclide subsequently releases radiation near or inside the tumor cell, causing DNA damage to inhibit or kill the tumor cell. PRRT precisely uses radiolabeled peptides to selectively target tumor cells that express the corresponding receptors, delivering therapeutic radiation to ...
- Source: drugdu
- 174
- October 2, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.